Molecular pathology of non-invasive urothelial carcinomas (part I)

被引：29

作者：

Helpap, B ^{[1
]}

Schmitz-Dräger, BJ

Hamilton, PW

Muzzonigro, G

Galosi, AB

Kurth, KH

Lubaroff, D

Waters, DJ

Droller, MJ

机构：

[1] Hegau Klinikum, Inst Pathol, D-78207 Singen, Germany

[2] Euromed Clin, Dept Urol, D-90763 Furth, Germany

[3] Ctr Hlth Care Informat, Dept Pathol, Belfast, Antrim, North Ireland

[4] Univ Ancona, Azienda Osped Umberto 1, Inst Urol, Ancona, Italy

[5] Univ Amsterdam, Dept Urol, Amsterdam, Netherlands

[6] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA

[7] Gerald P Murphy Canc Fdn, Seattle, WA USA

[8] Mt Sinai Med Ctr, Dept Urol, New York, NY 10029 USA

来源：

VIRCHOWS ARCHIV | 2003年 / 442卷 / 04期

关键词：

papillary bladder cancer; non-invasive; cell proliferation; cytokeratins; tumor suppressor genes;

D O I：

10.1007/s00428-002-0748-0

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

An international consultation on the diagnosis of non-invasive urothelial neoplasms was held in Ancona, Italy in May 2001. Besides histology and problems of classification, one group of experts (Committee no. 3) discussed the molecular pathology and cytometry of non-invasive urothelial carcinomas. In the following first part, special immunohistochemical and molecular markers for stratifications in bladder cancer were discussed including different cytokeratins (clone 34betaE12, CK 20), cell proliferation markers (Ki67/MIB-1, PCNA, AgNOR, DNA-cytometry), tumor suppressor genes and oncogenes (p53. p21. erb-132, bcl-2), different receptor expressions of epidermal growth factor and vascular endothelial growth factor and others. These molecular markers were analyzed in diagnosis of urothelial carcinomas, recurrences, progression and response to treatment.

引用

页码：309 / 316

页数：8

共 54 条

[1] Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors [J].

Alsheikh, A ;

Mohamedali, Z ;

Jones, E ;

Masterson, J ;

Gilks, CB .

MODERN PATHOLOGY, 2001, 14 (04) :267-272

[2] Immunohistochemical determination of p53 overexpression - An easy and readily available method to identify progression in superficial bladder cancer? [J].

Burkhard, FC ;

Markwalder, R ;

Thalmann, GN ;

Studer, UE .

UROLOGICAL RESEARCH, 1997, 25 (Suppl 1) :S31-S35

[3] Nuclear accumulation of mutant p53 protein: A possible predictor of failure of intravesical therapy in bladder cancer [J].

Caliskan, M ;

Turkeri, LN ;

Mansuroglu, B ;

Toktas, G ;

Aksoy, B ;

Unluer, E ;

Akdas, A .

BRITISH JOURNAL OF UROLOGY, 1997, 79 (03) :373-377

[4]

Casetta G, 1997, EUR UROL, V32, P229

[5]

Chow NH, 2000, ANTICANCER RES, V20, P1173

[6]

Cote RJ, 1998, CANCER RES, V58, P1090

[7] Loss of heterozygosity on chromosomes 11 and 17 are markers of recurrence in TCC of the bladder [J].

Edwards, J ;

Duncan, P ;

Going, JJ ;

Grigor, KM ;

Watters, AD ;

Bartlett, JMS .

BRITISH JOURNAL OF CANCER, 2001, 85 (12) :1894-1899

[8]

FLAM TA, 1990, EUR UROL, V17, P338

[9] Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder [J].

Friedrich, MG ;

Riethdorf, S ;

Erbersdobler, A ;

Tiemer, C ;

Schwaibold, H ;

Sölter, JK ;

Huland, E ;

Riethdorf, L ;

Conrad, S ;

Hammerer, PG ;

Huland, H .

EUROPEAN UROLOGY, 2001, 39 (02) :159-166

[10] IMMUNOHISTOLOGICAL EXPRESSION OF P53 IN PRIMARY PT1 TRANSITIONAL-CELL BLADDER-CANCER IN RELATION TO TUMOR PROGRESSION [J].

GARDINER, RA ;

WALSH, MD ;

ALLEN, V ;

RAHMAN, S ;

SAMARATUNGA, MLTH ;

SEYMOUR, GJ ;

LAVIN, MF .

BRITISH JOURNAL OF UROLOGY, 1994, 73 (05) :526-532

← 1 2 3 4 5 6 →